Navigation Links
Curemark Announces Four New Sites Participating in Autism Study
Date:12/2/2010

RYE, N.Y., Dec. 2, 2010 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism treatment CM-AT.  The new trial sites are:

  • Institute for Behavioral Medicine, Smyrna, Georgia
  • Cyn3rgy Research, Gresham, Oregon
  • Westside Medical Clinic, Clinton, Utah
  • Oklahoma University Physician's Child Study Center, Oklahoma City

There are now a total of 19 sites nationally conducting Phase III trials for Curemark's autism therapy.  The study is targeting a total enrollment of 170 children.

"We have been extremely pleased with the response and the level of participation in the CM-AT autism study," said Dr. Joan Fallon, Curemark founder and CEO.  "Enrollment is continuing to proceed well at our other trial sites throughout the country."

CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
2. Curemark Moderates Autism Panel at Life Sciences Summit 2010
3. Curemark Presents at the Rodman & Renshaw Annual Global Investment Conference
4. James F. Szigethy Named Curemarks Director of New Product Development
5. Curemark to Present at BioPharm America™ 2010
6. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
7. Curemark Opens Autism Trials at New Jersey Site
8. Curemark Begins Autism Trials at Two More Sites
9. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
10. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
11. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... 4, 2016 In response to the opioid abuse ... Commissioner for Medical Products and Tobacco, along with other FDA ... agency,s approach to opioid medications. The plan will focus on ... in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure that ...
Breaking Medicine Technology:
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... ... autism conference held annually in this country. The AutismOne 2016 Conference, which is being ... the truth they often won’t hear elsewhere about helpful interventions and causes of chronic ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... MyDecision™ empowers employers and organizations with the tools and information to lower the ... elements to cut the cost of providing employee healthcare benefits by as much ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX LUT: Summer ... grades to their footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. By manipulating each pixel, LUT's can change each color ...
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at King Kullen! ... assortments and packaging. This staple for Valentine’s Day is a must-have, and can be ... Valentine’s Day, not only are long-stem roses available, but also other flower bouquets, elegantly ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):